trial

15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated

NCTId NCT01157351
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 450 (actual)
Sponsored by Janssen, L.P. - Investigator Initiated Studies Program
Primary completion 2013-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
450 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2010-05
Primary completion
2013-12
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
PaliperidoneRisperidoneHaloperidolPerphenazineAripiprazoleQuetiapineOlanzapine

Sponsors

Janssen, L.P. - Investigator Initiated Studies ProgramLead Sponsor

Sites

0 total

Facts & assertions

4 sourced
Enrollment
450
Phase
PHASE4
Primary Completion Date
2013-12
Status
COMPLETED
relationships
The graph out of here
drug
Paliperidone
drug
Risperidone
drug
Haloperidol
drug
Perphenazine
drug
Aripiprazole
drug
Quetiapine
drug
Olanzapine
drug
lead_sponsor
Janssen, L.P. - Investigator Initiated Studies Program
company
indication
Schizophrenia
indication
Schizophrenia
indication